A new mouse study shows that inherited genetic background shapes cancer development after the same DNA-damaging exposure, linking germline variation to later tumor evolution.

The researchers find that inherited genetics influence both mutation processes and pathway choices, suggesting DNA-damaging therapies may have varying effectiveness across individuals beyond standard clinical factors.

Using four genetically diverse mouse strains and controlled exposure to the liver carcinogen diethylnitrosamine, the study isolates genetic background effects from environment, revealing that cancer pathways and genomic instability can be directed by inherited genetics.

A notable divergence was a higher tendency for whole-genome duplication in some lineages, which can accelerate tumor evolution by providing extra genetic material for selection.

The study was primarily conducted at the CRUK Cambridge Institute with international collaboration and was published in Nature.

Key researchers include Duncan Odom, Dr. Sarah Aitken, and Professor Martin Taylor, with international collaboration across Europe and the United States.

Funders include Cancer Research UK, the Medical Research Council, the European Research Council, and Wellcome, underscoring broad support for researching how inherited genetics interact with environmental exposures to influence cancer.

Incorporating population diversity and inherited genomic context into prevention and precision oncology could improve prognostic power and targeting of therapies.

Implications point toward changes in cancer screening, prevention, and precision medicine, emphasizing the need to account for population diversity and individual genetic backgrounds in risk assessment and treatment planning.

Overall, cancer care may require precision medicine that accounts for population diversity and each person's genetic background across prevention, screening, and treatment strategies.

All tumors activated the MAPK signaling pathway, but the driver mutations and evolutionary trajectories varied by genetic background, with some strains showing a higher tendency for events like whole-genome duplication.

Despite differing genetic backgrounds, tumors often converged on MAPK pathway activation, indicating shared cancer-promoting outcomes driven by DNA damage, while the specific drivers differed by background.